Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has granted 1,350 restricted stock units to one newly hired employee. The grant was approved by the company's Compensation Committee under the 2018 Inducement Plan, effective February 3, 2025. The stock units will vest over a four-year period, with 25% vesting after the first anniversary and the remaining portions vesting in 12 quarterly installments over the following three years, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Atara Biotherapeutics (Nasdaq: ATRA), leader nell'immunoterapia con cellule T, ha assegnato 1.350 unità di azioni vincolate a un nuovo dipendente. L'assegnazione è stata approvata dal Comitato per la Compensazione dell'azienda ai sensi del Piano di Induzione del 2018, con effetto dal 3 febbraio 2025. Le unità di azioni matureranno nel corso di un periodo di quattro anni, con il 25% che matura dopo il primo anniversario e le restanti quote che maturano in 12 rate trimestrali nei tre anni successivi, a condizione di un impiego continuato. Questa concessione è stata effettuata in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) come incentivo per l'impiego.
Atara Biotherapeutics (Nasdaq: ATRA), líder en inmunoterapia con células T, ha otorgado 1,350 unidades de acciones restringidas a un nuevo empleado. La concesión fue aprobada por el Comité de Compensación de la empresa bajo el Plan de Inducción de 2018, con fecha efectiva del 3 de febrero de 2025. Las unidades de acciones se consolidarán durante un período de cuatro años, con un 25% consolidándose después del primer aniversario y las porciones restantes consolidándose en 12 cuotas trimestrales durante los tres años siguientes, condicionado a la continuidad del empleo. Esta concesión se realizó de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4) como un incentivo para el empleo.
Atara Biotherapeutics (Nasdaq: ATRA), T세포 면역치료의 선두주자로, 새로운 직원에게 1,350개의 제한 주식 단위를 부여했습니다. 이 부여는 2018년 유인 계획에 따라 회사의 보상 위원회에 의해 승인되었으며, 2025년 2월 3일부터 시행됩니다. 주식 단위는 4년 동안 분할되어, 첫 번째 기념일 후 25%가 확정되고 나머지 부분은 향후 3년 동안 매 분기 12회에 걸쳐 확정됩니다. 이 부여는 지속적인 고용 조건에 따라 이루어졌습니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유인을 위해 제공되었습니다.
Atara Biotherapeutics (Nasdaq: ATRA), un leader dans l'immunothérapie par cellules T, a accordé 1 350 unités d'actions restreintes à un nouvel employé. L'attribution a été approuvée par le Comité de Compensation de l'entreprise dans le cadre du Plan d'Induction de 2018, entré en vigueur le 3 février 2025. Les unités d'actions seront acquises sur une période de quatre ans, avec 25 % devenant acquises après le premier anniversaire et les portions restantes acquises en 12 paiements trimestriels au cours des trois années suivantes, sous réserve d'un emploi continu. Cette attribution a été faite conformément à la Règle de Cotation Nasdaq 5635(c)(4) en tant qu'incitation à l'emploi.
Atara Biotherapeutics (Nasdaq: ATRA), ein führendes Unternehmen in der T-Zell-Immuntherapie, hat 1.350 eingeschränkte Aktieneinheiten an einen neu eingestellten Mitarbeiter vergeben. Die Vergabe wurde vom Vergütungsausschuss des Unternehmens im Rahmen des Induktionsplans von 2018 genehmigt und tritt am 3. Februar 2025 in Kraft. Die Aktieneinheiten werden über einen Vierjahreszeitraum fällig, wobei 25% nach dem ersten Jubiläum fällig wird und die verbleibenden Anteile in 12 vierteljährlichen Raten über die folgenden drei Jahre fällig werden, vorausgesetzt, das Beschäftigungsverhältnis bleibt bestehen. Diese Vergabe erfolgte gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz zur Einstellung.
- None.
- None.
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250207852200/en/
Investor and Media Relations:
Jason Awe, Ph.D.
Head of Corporate Communications & Investor Relations
(805) 217-2287
jawe@atarabio.com
Source: Atara Biotherapeutics, Inc.
FAQ
How many restricted stock units did Atara Biotherapeutics (ATRA) grant in February 2025?
What is the vesting schedule for ATRA's February 2025 restricted stock units grant?
Under which plan were ATRA's February 2025 restricted stock units granted?
What is the purpose of ATRA's February 2025 restricted stock unit grant?
